Atulya (Atul) Deodhar

Professor

  • 4960 Citations
  • 36 h-Index
19942018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 8 Similar Profiles
Ankylosing Spondylitis Medicine & Life Sciences
Psoriatic Arthritis Medicine & Life Sciences
Placebos Medicine & Life Sciences
Rheumatoid Arthritis Medicine & Life Sciences
Rheumatology Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Tumor Necrosis Factor-alpha Medicine & Life Sciences
Safety Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1994 2018

1 Citations

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis

Van Der Heijde, D., Deodhar, A., Fitzgerald, O., Fleischmann, R., Gladman, D., Gottlieb, A. B., Hoepken, B., Bauer, L., Irvin-Sellers, O., Khraishi, M., Peterson, L., Turkiewicz, A., Wollenhaupt, J. & Mease, P. J., Jan 1 2018, In : RMD Open. 4, 1, e000582.

Research output: Contribution to journalArticle

Psoriatic Arthritis
Randomized Controlled Trials
Placebos
Safety
Psoriasis

Advances in spondyloarthritis: Glimpse in the future

Deodhar, A. A., Jul 1 2018, In : Current Opinion in Rheumatology. 30, 4, p. 301-302 2 p.

Research output: Contribution to journalEditorial

1 Citations

Complementary medicine for axial spondyloarthritis: Is there any scientific evidence?

Danve, A. & Deodhar, A. A., Jul 1 2018, In : Current Opinion in Rheumatology. 30, 4, p. 310-318 9 p.

Research output: Contribution to journalReview article

Complementary Therapies
Yoga
Tai Ji
Clinical Trials
Safety Management
1 Citations

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study

Landewé, R., Sieper, J., Mease, P., Inman, R. D., Lambert, R. G., Deodhar, A., Marzo-Ortega, H., Magrey, M., Kiltz, U., Wang, X., Li, M., Zhong, S., Mostafa, N. M., Lertratanakul, A., Pangan, A. L. & Anderson, J. K., Jan 1 2018, (Accepted/In press) In : The Lancet.

Research output: Contribution to journalArticle

Double-Blind Method
Safety
Therapeutics
Placebos
Adalimumab
3 Citations

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

van der Heijde, D., Baraliakos, X., Gensler, L. S., Maksymowych, W. P., Tseluyko, V., Nadashkevich, O., Abi-Saab, W., Tasset, C., Meuleners, L., Besuyen, R., Hendrikx, T., Mozaffarian, N., Liu, K., Greer, J. M., Deodhar, A. A. & Landewé, R., Jan 1 2018, (Accepted/In press) In : The Lancet.

Research output: Contribution to journalArticle

Janus Kinase 1
Ankylosing Spondylitis
Placebos
Safety
Therapeutics